NCT01833208View on ClinicalTrials.gov

Radiation Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Receiving Sipuleucel-T

NACompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

July 3, 2013

Primary Completion Date

August 6, 2018

Study Completion Date

January 23, 2021

Conditions
Hormone-Resistant Prostate CancerMetastatic Malignant Neoplasm in the BoneRecurrent Prostate CarcinomaStage IV Prostate Cancer
Interventions
OTHER

Laboratory Biomarker Analysis

Correlative studies

RADIATION

Radiation Therapy

Undergo single-fraction radiation therapy

Trial Locations (2)

14225

Western New York Urology Associates LLC-Harlem, Cheektowaga

14263

Roswell Park Cancer Institute, Buffalo

Sponsors

Collaborators (1)

Dendreon
All Listed Sponsors
collaborator

Dendreon

INDUSTRY

lead

Roswell Park Cancer Institute

OTHER

NCT01833208 - Radiation Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Receiving Sipuleucel-T | Biotech Hunter | Biotech Hunter